Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Transcriptional regulators CITED2 and PU.1 cooperate in maintaining hematopoietic stem cells.

Mattes K, Geugien M, Korthuis PM, Brouwers-Vos AZ, Fehrmann RSN, Todorova TI, Steidl U, Vellenga E, Schepers H.

Exp Hematol. 2019 May;73:38-49.e7. doi: 10.1016/j.exphem.2019.03.003. Epub 2019 Apr 13.

PMID:
30986495
2.

Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones.

de Boer B, Prick J, Pruis MG, Keane P, Imperato MR, Jaques J, Brouwers-Vos AZ, Hogeling SM, Woolthuis CM, Nijk MT, Diepstra A, Wandinger S, Versele M, Attar RM, Cockerill PN, Huls G, Vellenga E, Mulder AB, Bonifer C, Schuringa JJ.

Cancer Cell. 2018 Oct 8;34(4):674-689.e8. doi: 10.1016/j.ccell.2018.08.014. Epub 2018 Sep 20.

PMID:
30245083
3.

BRD3/4 inhibition and FLT3-ligand deprivation target pathways that are essential for the survival of human MLL-AF9+ leukemic cells.

Carretta M, Brouwers-Vos AZ, Bosman M, Horton SJ, Martens JHA, Vellenga E, Schuringa JJ.

PLoS One. 2017 Dec 14;12(12):e0189102. doi: 10.1371/journal.pone.0189102. eCollection 2017.

4.

Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches.

Antonelli A, Noort WA, Jaques J, de Boer B, de Jong-Korlaar R, Brouwers-Vos AZ, Lubbers-Aalders L, van Velzen JF, Bloem AC, Yuan H, de Bruijn JD, Ossenkoppele GJ, Martens AC, Vellenga E, Groen RW, Schuringa JJ.

Blood. 2016 Dec 22;128(25):2949-2959. doi: 10.1182/blood-2016-05-719021. Epub 2016 Oct 12.

5.

Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.

Sontakke P, Carretta M, Jaques J, Brouwers-Vos AZ, Lubbers-Aalders L, Yuan H, de Bruijn JD, Martens AC, Vellenga E, Groen RW, Schuringa JJ.

Leukemia. 2016 Oct;30(10):2064-2073. doi: 10.1038/leu.2016.108. Epub 2016 Apr 29.

PMID:
27125308
6.

Hypoxia-Like Signatures Induced by BCR-ABL Potentially Alter the Glutamine Uptake for Maintaining Oxidative Phosphorylation.

Sontakke P, Koczula KM, Jaques J, Wierenga AT, Brouwers-Vos AZ, Pruis M, Günther UL, Vellenga E, Schuringa JJ.

PLoS One. 2016 Apr 7;11(4):e0153226. doi: 10.1371/journal.pone.0153226. eCollection 2016.

7.

Non-canonical PRC1.1 Targets Active Genes Independent of H3K27me3 and Is Essential for Leukemogenesis.

van den Boom V, Maat H, Geugien M, Rodríguez López A, Sotoca AM, Jaques J, Brouwers-Vos AZ, Fusetti F, Groen RW, Yuan H, Martens AC, Stunnenberg HG, Vellenga E, Martens JH, Schuringa JJ.

Cell Rep. 2016 Jan 12;14(2):332-46. doi: 10.1016/j.celrep.2015.12.034. Epub 2015 Dec 31.

8.

The TAK1-NF-κB axis as therapeutic target for AML.

Bosman MC, Schepers H, Jaques J, Brouwers-Vos AZ, Quax WJ, Schuringa JJ, Vellenga E.

Blood. 2014 Nov 13;124(20):3130-40. doi: 10.1182/blood-2014-04-569780. Epub 2014 Oct 6.

9.

Aging impairs long-term hematopoietic regeneration after autologous stem cell transplantation.

Woolthuis CM, Mariani N, Verkaik-Schakel RN, Brouwers-Vos AZ, Schuringa JJ, Vellenga E, de Wolf JT, Huls G.

Biol Blood Marrow Transplant. 2014 Jun;20(6):865-71. doi: 10.1016/j.bbmt.2014.03.001. Epub 2014 Mar 7.

10.

Loss of quiescence and impaired function of CD34(+)/CD38(low) cells one year following autologous stem cell transplantation.

Woolthuis CM, Brouwers-Vos AZ, Huls G, de Wolf JT, Schuringa JJ, Vellenga E.

Haematologica. 2013 Dec;98(12):1964-71. doi: 10.3324/haematol.2013.086744. Epub 2013 Sep 13.

Supplemental Content

Loading ...
Support Center